慢性心不全患者の鉄欠乏症の再定義
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。心不全における鉄欠乏に対する現在のフェリチンベースの定義は信頼できない. より正確なアプローチは,鉄療法の恩恵を受ける患者を特定するために,トランスファーリン飽和度 (TSAT) <20%を使用します.
科学分野
- 心臓病科
- 血液学
- 内科 医学
背景
- 慢性腎臓病と炎症状態による心不全の患者では,鉄欠乏症を特定するための従来の血清フェリチン値が不正確です.
- 鉄欠乏症に対する現在のガイドラインは,フェリチン濃度の上昇に基づいて,患者を誤って特定し,鉄療法に対する反応を確実に予測することはできません.
- ネプリリシンやナトリウム・グルコース・コトランスポーター2阻害剤のような薬は,血清フェリチンレベルをさらに歪めることができます.
研究 の 目的
- 心不全における鉄欠乏の現在のフェリチン主導の定義の有効性を評価する.
- 心不全患者の鉄欠乏症の代替的な根拠に基づく定義を提案する.
- トランスファーリン飽和度 (TSAT) <20%で示される低フェルレミアが,鉄欠乏症と鉄療法への反応のより信頼できるマーカーであるかどうかを判断する.
主な方法
- 鉄欠乏症の定義と心不全における治療結果に関する既存の文献と臨床試験のデータをレビューする.
- 血清フェリチンとTSATの診断精度の分析 骨髄検査で確認された鉄欠乏状態の特定
- 異なる鉄欠乏症の定義に基づいて,機能能力と心血管の結果に対する鉄療法の影響の評価.
主要な成果
- 現在のフェリチンベースの定義は,鉄欠乏症でない患者を誤って含み,鉄欠乏症から恩恵を受ける患者を除外しています.
- TSAT < 20% (低血圧症) は,骨髄検査で確認された鉄欠乏症の患者を確実に特定します.
- 静脈内鉄療法により,運動耐性が改善され,心血管疾患による死亡や心不全による入院が20%~30%減少しました.
結論
- 心不全における鉄欠乏のフェリチン主導の定義は放棄されるべきである.
- 鉄血症 (TSAT < 20%) に基づく定義は,鉄療法の恩恵を受ける心不全患者の特定のために,より証拠に基づいた,臨床的に関連しています.
- 20%未満のTSAT値を採用すると,鉄補給戦略を最適化し,心不全の患者のアウトカムを改善することができます.
関連する概念動画
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...